| Latest | F'cast | |
|---|---|---|
| Div Yield | 0.0% | 0.0% |
| Div Cover | n/a | n/a |
| Op Mrgn | n/a | n/a |
| ROCE | n/a |
| Latest | F'cast | |
|---|---|---|
| P/E | n/a | n/a |
| PEG | n/a | n/a |
| Pr/Revenue | n/a | n/a |
| Pr/Book | 4.8 |
| Latest | F'cast | |
|---|---|---|
| Revenue | n/a | n/a |
| PBT | n/a | n/a |
| EPS | n/a | n/a |
| DPS | n/a | n/a |
| Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 31-Dec-20 | n/a | (2.67) | 0.00¢ | n/a | n/a | n/a | n/a | 0.0% |
| 31-Dec-21 | n/a | (1.79) | (0.13)¢ | n/a | n/a | n/a | n/a | 0.0% |
| 31-Dec-22 | n/a | (2.61) | (0.19)¢ | n/a | n/a | n/a | n/a | 0.0% |
| 31-Dec-23 | 0.04 | (0.20) | (1,225.00)p | n/a | n/a | n/a | n/a | 0.0% |
| 31-Dec-24 | n/a | (0.59) | (0.01)p | n/a | n/a | n/a | n/a | 0.0% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
| Board Changes | 02-Apr-2026 | 07:00 | RNS |
| Phase 2 Clinical Trial Progress Update | 25-Mar-2026 | 07:00 | RNS |
| Awarding of Orphan Drug Designation by the FDA | 17-Mar-2026 | 07:00 | RNS |
No deals were found in the last 28 days.
| Currency | UK Pounds |
| Share Price | 11.00p |
| Change Today | -0.75p |
| % Change | -6.38 % |
| 52 Week High | 11.80 |
| 52 Week Low | 10.50 |
| Volume | 637,755 |
| Shares Issued | 51.74m |
| Market Cap | £5.69m |
| Value |
|
|---|
| Value |
|
|---|
| Income | ![]() |
|---|
| Growth | ![]() |
|---|
| Latest | Previous | |
|---|---|---|
| Special | Interim | |
| Ex-Div | 01-Jun-23 | n/a |
| Paid | 14-Jun-23 | n/a |
| Amount | 1.80p | 0.000¢ |
| Time | Volume / Share Price |
| 15:25 | 54,748 @ 10.95p |
| 13:47 | 3,232 @ 10.58p |
| 12:00 | 80,000 @ 10.60p |
| 12:33 | 2,361 @ 10.58p |
| 12:01 | 229 @ 11.50p |
You are here: research